Search Results - "Ribaldone D"

Safety, Tolerability and RealWorld Effectiveness of Recombinant Zoster Vaccine (Shingrix®) in Patients with Inflammatory Bowel Disease: A Prospective SingleCentre Cohort.

Authors: Ribaldone, D. G. Vernero, M. Stella, A.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi1972-i1972. 1p.

Use of Risankizumab in Patient with Psoriasis and Crohn Disease: A Multicenter Study.

Authors: Ribaldone, D. G. Mastorino, L. Bezzio, C. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi1810-i1810. 1p.

Crohn's Disease Exclusion Diet (CDED) plus Partial Enteral Nutrition versus Oral Steroids for Induction and Maintenance of Remission in Adult Crohn's Disease: A Prospective Case-Control Study.

Authors: Ribaldone, D. G. Dileo, I. Chiarotto, A. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi1271-i1271. 1p.

Periodontal Inflammation Predicts the Clinical Course of Inflammatory Bowel Disease: A RealWorld Longitudinal Cohort Study.

Authors: Ribaldone, D. G. Romano, F. Muwalla, M. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi1268-i1268. 1p.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Letter: therapeutic drug monitoring and inflammatory bowel disease—a call for an urgent standardization of the results.

Authors: Ribaldone, D. G. Saracco, G. M. Astegiano, M. et al.

Source: Alimentary Pharmacology & Therapeutics. Feb2018, Vol. 47 Issue 3, p448-449. 1p.

Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti- TNF therapy?

Authors: Ribaldone, D. G. Saracco, G. Astegiano, M. et al.

Source: Alimentary Pharmacology & Therapeutics. Jan2018, Vol. 47 Issue 1, p146-147. 1p.

This result is not displayed to guests.
Login for full access.

Effect of IL-23 inhibitors on extra-intestinal manifestations and concurrent immune-mediated inflammatory diseases in patients with inflammatory bowel disease.

Authors: Truyens, M. Tolstoy, X. Calabrese, G. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi2069-i2073. 5p.

Effect of JAK inhibitors on extra-intestinal manifestations and concurrent immune-mediated inflammatory diseases in patients with inflammatory bowel disease.

Authors: Truyens, M. Tolstoy, X. Calabrese, G. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi2000-i2004. 5p.

MIRACLE-UC: Mirikizumab Investigation of Real-world Assessment of Clinical and Long-term Effectiveness and Adverse Events in Patients with Ulcerative Colitis - A Multicenter Prospective Study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

Authors: Barberio, B. Todeschini, A. Laterza, L. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi1625-i1628. 4p.

Does Helicobacter pylori infection increase the risk of adult-onset asthma?

Authors: Ribaldone, D. Saracco, G. Pellicano, R.

Source: European Journal of Clinical Microbiology & Infectious Diseases. Oct2017, Vol. 36 Issue 10, p1995-1996. 2p.

Risk of relapse and retreatment success after vedolizumab discontinuation in patients with IBD in long-standing remission: a retrospective study from the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD).

Authors: Dragoni, G. MD, T. Innocenti Festa, S. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi1756-i1758. 3p.

Upadacitinib: Personalized Goals for Remission and Disease Evaluation in Patients with Crohn’s Disease (UPGRADE-CD) - A Multicenter Prospective Study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

Authors: Barberio, B. Scaldaferri, F. Bezzio, C. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi174-i176. 3p.

Transition of Pediatric-Onset Inflammatory Bowel Disease to Adult Care: A Multicenter Italian Cohort Study.

Authors: Orrù, G. Onidi, M. F. Ceccarelli, L. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi3006-i3007. 2p.

An inverse propensity score-weighted comparison between Vedolizumab, Ustekinumab, and Tofacitinib in ulcerative colitis patients refractory or intolerant to anti-TNF therapies.

Authors: Mocci, G. Savarino, E. V. Bertin, L. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi2367-i2368. 2p.

Patient-Physician mismatch in therapeutic targets for advanced therapy in inflammatory bowel disease patients: the PROMISE study.

Authors: MD- PhD, G. Fiorino Salice, M. Loy, L. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi1243-i1244. 2p.

Real-world effectiveness and safety of three JAK inhibitors for ulcerative colitis: an IPTW analysis from IN-IBD.

Authors: Mocci, G. Pasta, A. Elisei, W. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi302-i303. 2p.